Modern controlled human malaria infection (CHMI) clinical trials have almost entirely
focussed on Plasmodium falciparum, providing a highly informative means to investigate …

Background Interventions to interrupt transmission of malaria from humans to mosquitoes
represent an appealing approach to assist malaria elimination. A limitation has been the …

Plasmodium vivax remains an important cause of morbidity and mortality across the
Americas, Horn of Africa, East and South East Asia. Control of transmission has been …

Existing control measures have significantly reduced malaria morbidity and mortality in the
last two decades, although these reductions are now stalling. Significant efforts have been …

A safe and reproducible Plasmodium vivax infectious challenge method is required to
evaluate the efficacy of malaria vaccine candidates. Seventeen healthy Duffy (+) and five …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …

This paper summarizes our current understanding of the biology of Plasmodium vivax, how it
differs from Plasmodium falciparum, and how these differences explain the need for P. vivax …

There is inadequate understanding of the biology, pathology, transmission, and control of
Plasmodium vivax, the geographically most widespread cause of human malaria. During the …

Although Plasmodium falciparum is the leading cause of morbidity and mortality due to
malaria worldwide, nearly 2.5 billion people, mostly outside Africa, are also at risk from …

Malaria prevalence has declined in the past 10 years, especially outside of sub-Saharan
Africa. However, the proportion of cases due to Plasmodium vivax is increasing, accounting …